ClinicalTrials.gg
Active, not recruitingNCT07124923Updated Nov 12, 2026

Continuous Care Intervention in Primary Care to Improve Type 2 Diabetes Control in Terres de l'Ebre, Catalonia

An interventional study of Continuity-of-Care intervention in Diabetes Mellitus Type 2, sponsored by Institut Investigacio Sanitaria Pere Virgili. Active, not recruiting at 12 sites in Spain. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Institut Investigacio Sanitaria Pere Virgili · Not applicable, Interventional, and Other

How we know

Updated Nov 12, 2026Now Active, not recruitingPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
7,792
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 429 studies in Diabetes Mellitus, Type 2 with a site in Spain — 44 open to participants now, 55 under way, 18 of them phase 3. Diabetes Mellitus, Type 2 · Spain.

Planned enrollment
18th of 383
7,792 · median 484
Started
2025
with 17 others
No phase
77 of 429
17 open now
Primary completion
2026-07
later than 14 of 54 live
Registered
399th of 429
by date

Among the 429 studies in Diabetes Mellitus, Type 2 with a site in Spain, this one is the 18th largest by planned enrollment of the 383 interventional ones that give a count, is one of 18 that started in 2025, is one of 77 with no phase, reaches primary completion later than 14 of the 54 other live ones, and was the 399th registered.

Diabetes Mellitus, Type 2

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

44 of the 429 studies in Diabetes Mellitus, Type 2 with a site in Spain are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 429 studies in Diabetes Mellitus, Type 2 with a site in Spain, or all of them as a file.
02

Study summary

This randomized, parallel-group, cluster-randomized clinical trial evaluates the effectiveness of a continuity-of-care intervention to improve metabolic control in adults with type 2 diabetes mellitus (T2DM) in the Terres de l'Ebre health region. The intervention, led by the Endocrinology Service at Hospital de Tortosa Verge de la Cinta (HTVC), involves structured, multidisciplinary training and feedback provided by endocrinologists and nurse educators to primary care professionals. Training modules combine theoretical and practical content focused on current diabetes management.

Eleven primary care centers were randomized to intervention (n=5) or control (n=6) groups. Eligible participants are adult patients with an active diagnosis of T2DM for at least 12 months as of January 2025, registered in the eCAP system. Primary care professionals in intervention centers are offered the training intervention.

The intervention was conducted over one year (July 2025-July 2026). Quantitative data were collected at baseline, 6 months, and 12 months, with a further assessment planned at 24 months. The primary outcome is the between-group difference in mean HbA1c at 12 months, accounting for the cluster-randomized design. The 24-month assessment will evaluate the sustainability of the intervention effect. Six-month data are retained but are not included in the main effectiveness analysis.

Secondary outcomes include cardiovascular risk factors, diabetes complication screening, healthcare utilization, medication changes, and organizational variables. A qualitative component gathers professional input before and after the intervention to inform future implementation. Patient data are processed using appropriate confidentiality and data protection safeguards.

Read the detailed description

Type 2 diabetes mellitus (T2DM) is a highly prevalent chronic disease, accounting for approximately 90% of all diabetes cases, and is primarily managed in the primary care setting. The complexity of optimizing metabolic control in T2DM has increased, as current guidelines recommend a multifactorial approach that addresses not only glycemic control but also cardiovascular risk and multimorbidity. Glycated hemoglobin (HbA1c) remains a key marker for assessing glycemic control and the risk of diabetes-related complications.

Despite the availability of evidence-based clinical practice guidelines, their implementation in routine care is often suboptimal due to factors such as limited time, resources, clinical inertia, and challenges with patient adherence. Interventions targeting healthcare professionals and organizational processes, such as structured training, audit and feedback, and system-level changes, may improve metabolic outcomes.

This study is a parallel-group, cluster-randomized clinical trial designed to evaluate the effectiveness of a continuity-of-care intervention led by the Endocrinology Service at Hospital de Tortosa Verge de la Cinta (HTVC), in collaboration with primary care centers in the Terres de l'Ebre health region. Eleven primary care centers were randomized to the intervention (n=5) or control (n=6) group.

The intervention consists of structured, multidisciplinary training and feedback provided by endocrinologists and nurse educators to primary care physicians and nurses. Training sessions combine theoretical and practical content, focusing on current diabetes management strategies and the specific needs of each primary care center. The multidisciplinary team includes endocrinologists, diabetes nurse educators, and a specialist nurse from the Diabetic Foot Unit. Training was delivered onsite at intervention centers during scheduled sessions over a one-year period, from July 2025 to July 2026. Centers assigned to the control group continued usual care.

A qualitative component is integrated into the study, involving focus groups with primary care professionals before and after the intervention. This component aims to explore professional perspectives, identify barriers and facilitators, and inform future implementation of the intervention.

Quantitative data were collected at baseline (July 2025), 6 months, and 12 months (July 2026), with a further assessment planned at 24 months (July 2027). The primary outcome is the between-group difference in mean HbA1c at 12 months, analyzed according to the intention-to-treat principle and accounting for the cluster-randomized design. The 24-month assessment will evaluate the sustainability of the intervention effect. Six-month data are retained but will not be included in the main effectiveness analysis.

Secondary outcomes include cardiovascular risk factors, body mass index, smoking status, screening for diabetes-related complications, referrals to specialized care, emergency department visits, medication changes, and healthcare utilization.

Clinical data are obtained from electronic health records and processed in accordance with applicable data protection and confidentiality requirements.

This study aims to provide evidence on the effectiveness and sustainability of a multidisciplinary continuity-of-care intervention to improve metabolic control in adults with T2DM in a real-world primary care setting.

Protocol Amendment - Assessment Schedule and Data Extraction

The original protocol included quantitative assessments at baseline, 6, 12, and 24 months. During data quality review, it was identified that the electronic health record extraction labeled as the 12-month assessment contained data from the second six-month period rather than the complete first year of follow-up.

To reconstruct the first-year dataset, data from the 0-6-month and 6-12-month periods were combined. The 6-month data were retained, but the main effectiveness analysis was focused on the 12-month assessment, corresponding to the completion of the intervention, and the 24-month assessment, evaluating the sustainability of its effect.

This analytical decision was made before the investigators had access to the HbA1c results or between-group comparisons.

03

Conditions studied

  • Diabetes Mellitus Type 2

Keywords

  • HbA1c
  • Primary Care
  • Continuity of Care
  • Training
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Enrollment will begin in July 2025, aligned with the initiation of training sessions for healthcare professionals (physicians and nurses).

Eligible participants must:

  • Be adults (≥18 years old)
  • Have an active diagnosis of T2DM documented in the eCAP primary care electronic health record system
  • Have a duration of T2DM of at least 12 months as of January 2025

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of type 1 diabetes mellitus (T1DM)
  • T2DM managed by a specialist at the time of inclusion
  • Current treatment with systemic
  • Active neoplasia ()
  • Gestational diabetes
  • Pregnancy or breastfeeding
  • Diagnosis of MACA (advanced chronic disease with \<1 year)
  • Complex chronic patients (CCP)
  • Diagnosis of dementia
  • Institutionalized patients or those residing in social healthcare facilities
  • Age over 90 years
  • Age under 18 years
  • Severe psychiatric illness (e.g., psychosis, bipolar disorder, major depression)
  • History of kidney transplant
  • Undergoing dialysis
  • History of alcohol or drug abuse
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
7,792 participants (estimated)

Study arms

  • Experimental
    Continuity-of-Care Training for Primary Care Professionals

    A parallel-group randomized clinical trial will be conducted in 11 primary care centers of the Terres de l'Ebre area (Catalan Health Institute). Randomization was performed by the data extractor before pseudonymization using simple randomization (1:1 ratio), generating values 0 and 1. Centers scoring \<0.5 were assigned to the control group; those ≥0.5 to the intervention group, resulting in 5 intervention and 6 control centers.

    Other: Continuity-of-Care intervention

  • No intervention
    Usual Care (No Continuity-of-Care Training)

    Primary care professionals provide care according to current local standard practices without receiving specific training on continuity-of-care strategies.

Interventions

  • OtherContinuity-of-Care intervention

    The intervention is a structured, multidisciplinary training and feedback program led by the Endocrinology Service at HTVC in collaboration with primary care centers in Terres de l'Ebre. Four endocrinologists and four nurses (three educators and one diabetic foot referent) will provide onsite training to primary care physicians and nurses. Training includes six modules with theoretical and practical components, covering T2DM management, cardiovascular risk reduction, and diabetic foot care. Sessions will be held biweekly and delivered by doctor-nurse teams rotating through the participating primary care centers from July 2025 to July 2026, with each center receiving a total of 15 sessions per year. The program also includes regular feedback to professionals on clinical performance and patient outcomes, adapting content to each center's needs. A qualitative component, involving focus groups before and after the intervention, will gather feedback and inform future implementation.

06

What researchers measure

Primary outcomes

  1. Mean glycated hemoglobin (HbA1c) at 12 months

    The primary outcome is the adjusted between-group difference in mean HbA1c at 12 months, comparing patients from primary care centers randomized to the intervention with those randomized to usual care. HbA1c will be analyzed as a continuous variable, expressed as a percentage, according to the intention-to-treat principle. The primary analysis will use a longitudinal linear mixed-effects model accounting for clustering within primary care centers and repeated measurements within patients.

    Time frame: Baseline and 12 months after study start.

Secondary outcomes

  1. Change in total cholesterol and LDL cholesterol

    Mean change in total and LDL cholesterol levels from baseline, measured in mg/dL.

    Time frame: At baseline, 12 months, and 24 months after study start.

  2. Change in systolic and diastolic blood pressure

    Mean change in systolic and diastolic blood pressure from baseline, measured in mmHg.

    Time frame: At baseline, 12 months, and 24 months after study start.

  3. Change in smoking status

    Change in smoking status (current, former, never) and number of cigarettes smoked per day.

    Time frame: At baseline, 12 months, and 24 months after study start.

  4. Change in Body Mass Index (BMI)

    Mean change in BMI (Kg/m2) from baseline. BMI will be calculated as weight in kilograms divided by height in meters squared.

    Time frame: At baseline, 12 months, and 24 months after study start.

  5. Percentage of participants adherent to screening protocol for T2DM complications

    Percentage of participants who complete all recommended screenings for chronic complications of T2DM, including screening for retinopathy, nephropathy, foot examination, and cardiovascular assessment.

    Time frame: At baseline, 12 months, and 24 months after study start.

  6. Referrals to the Diabetic Foot Unit

    Evaluate the association between attendance at diabetic foot training and referrals to the Diabetic Foot Unit.

    Time frame: At baseline, 12 months, and 24 months after study start.

  7. Emergency assistance for metabolic decompensations

    Evaluate whether patients present to emergency care with a diagnosis of metabolism and nutrition disorder according to CIE-10 ( CIE-10 E00-E90)

    Time frame: At baseline, 12 months, and 24 months after study start.

  8. Number of hospital referrals from primary care

    Evaluate the number of hospital referrals to endocrinology specialty consultation after primary care attendance.

    Time frame: At baseline, 12 months, and 24 months after study start.

  9. Medication changes

    Assess the association between professional attendance at training and medication changes.

    Time frame: At baseline, 12 months, and 24 months after study start.

  10. Number of patient visits to primary care

    Evaluate the number of patient visits to primary care, stratified by nursing and physician attendance.

    Time frame: At baseline, 12 months, and 24 months after study start.

  11. Professional perceptions of relevance, feasibility and impact of the Continuity-of-Care intervention

    Professional perceptions of the Continuity-of-Care intervention will be assessed through pre- and post-intervention focus groups. Focus groups will be conducted with professionals from different disciplines (primary care doctors and nurses). Transcripts will be analyzed using thematic content analysis to assess perceptions of relevance, feasibility, and impact of the intervention.

    Time frame: Pre-intervention and 1 month post-intervention

  12. Professional experiences with implementing the Continuity-of-Care intervention, including perceived barriers and facilitators

    Professional experiences with implementing the Continuity-of-Care intervention will be assessed through pre- and post-intervention focus groups. Focus groups will be conducted with professionals from different disciplines (primary care doctors and nurses). Transcripts will be analyzed using thematic content analysis to assess experiences related to implementation and perceived barriers/facilitators.

    Time frame: Pre-intervention and 1 month post-intervention.

  13. Mean glycated hemoglobin (HbA1c) at 24 months

    The secondary outcome is the adjusted between-group difference in mean HbA1c at 24 months, comparing patients from primary care centers randomized to the intervention with those randomized to usual care. This assessment will evaluate the sustainability of the intervention effect one year after its completion. The analysis will account for clustering within primary care centers and repeated measurements within patients.

    Time frame: Baseline and 24 months after study start.

07

Study locations

12 sites
  • Abs Amposta
    Amposta, Tarragona 43870, Spain
  • Abs Deltebre
    Deltebre, Tarragona 43580, Spain
  • Abs Ametlla-Perelló
    El Perelló, Tarragona 43860, Spain
  • ABS FLIX
    Flix, TARRAGONA 43750, Spain
  • Abs Gandesa
    Gandesa, Tarragona 43780, Spain
  • Abs Ampolla-Aldea
    L'Ampolla, Tarragona 43895, Spain
  • Abs Mora La Nova
    Móra la Nova, Tarragona 43770, Spain
  • Abs La Ràpita-Alcanar
    Sant Carles de la Ràpita, Tarragona 43540, Spain
  • Abs Tortosa Est
    Tortosa, Tarragona 43500, Spain
  • Abs Tortosa Oest
    Tortosa, Tarragona 43500, Spain
  • Hospital de Tortosa Verge de la Cinta
    Tortosa, Tarragona 43500, Spain
  • Abs Ulldecona
    Ulldecona, Tarragona 43550, Spain
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Data sharing will be upon request directly to the Principal Investigator.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in Jul 2026, 12 months.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 12 months is below that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

Primary completion moved once since we started tracking on Sep 25, 2026: Jan 2026 → Jul 2026, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2025
First posted
Aug 15, 2025
StartActual
Jul 20, 2025
Primary completionActual
Jul 20, 2026was Jan 2026
CompletionEst.
Jul 20, 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 12, 2026
Sites
1 site added, 1 site removed
Show site
  • ABS FLIX · Flix, Spain
Show 1 removed
  • ABS FLIX · Flix, Spain
Nov 12, 2026
Primary completion
Jan 20, 2026→Jul 20, 2026 (actual)
Nov 12, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore HbA1cNow Mean glycated hemoglobin (HbA1c) at 12 monthsTime frame: At enrollment, 6, 12, and 24 months after enrollment. → Baseline and 12 months after study start.
Nov 12, 2026
Secondary outcomes
10 time frame changed, 1 added
What changed in the outcomes
  • AddedMean glycated hemoglobin (HbA1c) at 24 monthsTime frame: Baseline and 24 months after study start.
  • Time frameChange in total cholesterol and LDL cholesterolAt enrollment, 6, 12, and 24 months after enrollment. → At baseline, 12 months, and 24 months after study start.
  • Time frameChange in systolic and diastolic blood pressureAt enrollment, 6, 12, and 24 months after enrollment. → At baseline, 12 months, and 24 months after study start.
  • Time frameChange in smoking statusAt enrollment, 6, 12, and 24 months after enrollment. → At baseline, 12 months, and 24 months after study start.
  • Time frameChange in Body Mass Index (BMI)At enrollment, 6, 12, and 24 months after enrollment. → At baseline, 12 months, and 24 months after study start.
  • Time framePercentage of participants adherent to screening protocol for T2DM complicationsAt enrollment, 6, 12, and 24 months after enrollment. → At baseline, 12 months, and 24 months after study start.
  • Time frameReferrals to the Diabetic Foot UnitAt enrollment, 6, 12, and 24 months after enrollment. → At baseline, 12 months, and 24 months after study start.
  • Time frameEmergency assistance for metabolic decompensationsAt enrollment, 6, 12, and 24 months after enrollment. → At baseline, 12 months, and 24 months after study start.
  • Time frameNumber of hospital referrals from primary careAt enrollment, 6, 12, and 24 months after enrollment. → At baseline, 12 months, and 24 months after study start.
  • Time frameMedication changesAt enrollment, 6, 12, and 24 months after enrollment. → At baseline, 12 months, and 24 months after study start.
  • Time frameNumber of patient visits to primary careAt enrollment, 6, 12, and 24 months after enrollment. → At baseline, 12 months, and 24 months after study start.
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Recruiting→Active, not recruiting
    1 site added, 1 site removed
    Show site
    • ABS FLIX · Flix, Spain
    Show 1 removed
    • ABS FLIX · Flix, Spain
    Primary completion Jan 20, 2026→Jul 20, 2026 (now actual)
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore HbA1cNow Mean glycated hemoglobin (HbA1c) at 12 monthsTime frame: At enrollment, 6, 12, and 24 months after enrollment. → Baseline and 12 months after study start.
    Secondary outcomes 10 time frame changed, 1 added
    What changed in the outcomes
    • AddedMean glycated hemoglobin (HbA1c) at 24 monthsTime frame: Baseline and 24 months after study start.
    • Time frameChange in total cholesterol and LDL cholesterolAt enrollment, 6, 12, and 24 months after enrollment. → At baseline, 12 months, and 24 months after study start.
    • Time frameChange in systolic and diastolic blood pressureAt enrollment, 6, 12, and 24 months after enrollment. → At baseline, 12 months, and 24 months after study start.
    • Time frameChange in smoking statusAt enrollment, 6, 12, and 24 months after enrollment. → At baseline, 12 months, and 24 months after study start.
    • Time frameChange in Body Mass Index (BMI)At enrollment, 6, 12, and 24 months after enrollment. → At baseline, 12 months, and 24 months after study start.
    • Time framePercentage of participants adherent to screening protocol for T2DM complicationsAt enrollment, 6, 12, and 24 months after enrollment. → At baseline, 12 months, and 24 months after study start.
    • Time frameReferrals to the Diabetic Foot UnitAt enrollment, 6, 12, and 24 months after enrollment. → At baseline, 12 months, and 24 months after study start.
    • Time frameEmergency assistance for metabolic decompensationsAt enrollment, 6, 12, and 24 months after enrollment. → At baseline, 12 months, and 24 months after study start.
    • Time frameNumber of hospital referrals from primary careAt enrollment, 6, 12, and 24 months after enrollment. → At baseline, 12 months, and 24 months after study start.
    • Time frameMedication changesAt enrollment, 6, 12, and 24 months after enrollment. → At baseline, 12 months, and 24 months after study start.
    • Time frameNumber of patient visits to primary careAt enrollment, 6, 12, and 24 months after enrollment. → At baseline, 12 months, and 24 months after study start.
    + 3 other changes: verification date, description and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07124923
Lead sponsor
Institut Investigacio Sanitaria Pere Virgili
Responsible party
Sponsor
First posted
Aug 15, 2025
Start date
Jul 20, 2025
Primary completion
Jul 20, 2026
Completion
Jul 20, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Marcela Miret Llauradó, MD
principal investigator · Catalan Institute of Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion